Stockscreener 앱 받기
23.24
3.93%
-0.9302
전일 마감가:
$24.17
열려 있는:
$24.02
하루 거래량:
334.52K
Relative Volume:
0.12
시가총액:
$1.27B
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-28.00
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-4.64%
1개월 성능:
-19.65%
6개월 성능:
+240.47%
1년 성능:
+59.81%
1일 변동 폭
$23.01
$24.14
1주일 범위
$23.01
$25.70
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
23.26 | 1.31B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.03 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.68 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.75 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.13 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.31 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February - TradingView — Track All Markets
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)? - simplywall.st
Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? - Yahoo Finance
Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance
Capricor Updates Deramiocel BLA Status After FDA Review of HOPE-3 Data - filmogaz.com
CAPR stock slides after FDA requests more data for genetic disorder therapy — what does retail think? - MSN
Capricor Therapeutics (CAPR) Valuation After FDA Requests HOPE-3 Data For Deramiocel Regulatory Review - Yahoo Finance
Capricor (CAPR) Plans February FDA Data Submission After 2% Stock Drop - Intellectia AI
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? - Stocktwits
FDA Requests Capricor To Submit HOPE-3 Clinical Study Report For Deramiocel BLA Review - RTTNews
Capricor Therapeutics Provides Regulatory Updates Regarding Its Biologics License Application for Deramiocel - marketscreener.com
Capricor Therapeutics (CAPR) Moves Forward with Regulatory Update on Cell Therapy - GuruFocus
Capricor Therapeutics Inc. Provides Regulatory Update on Deramiocel BLA Submission Following FDA Request for HOPE-3 Clinical Study Report - Quiver Quantitative
FDA asks for full HOPE-3 data on DMD cell therapy, no new trials - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com UK
Cantor Fitzgerald reiterates Overweight rating on Capricor stock By Investing.com - Investing.com UK
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Phase 3 Success And Nippon Shinyaku Deals - Sahm
EV Market: Whats the profit margin of Capricor Therapeutics Inc2025 Major Catalysts & Smart Swing Trading Techniques - baoquankhu1.vn
Why Capricor Therapeutics Inc. stock attracts high net worth investorsStock Surge & Risk Controlled Daily Plans - Улправда
Capricor Therapeutics: A High Risk/High Reward Name - Seeking Alpha
Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal - Sahm
Here's Why This Biotechnology Skyrocketed by 439% in December - Yahoo Finance
How interest rate cuts could boost Capricor Therapeutics Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - ulpravda.ru
Investment Recap: How interest rate cuts could boost Capricor Therapeutics Inc. stockJuly 2025 Reactions & Weekly Top Stock Performers List - ulpravda.ru
Can Capricor Therapeutics Inc. stock weather global recession2025 Geopolitical Influence & Technical Pattern Recognition Alerts - ulpravda.ru
Capricor Therapeutics, Inc.Common Stock (NQ: CAPR - FinancialContent
(CAPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8%What's Next? - MarketBeat
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat
‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% - MSN
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5%Here's What Happened - MarketBeat
Best Biotech Stocks To ConsiderDecember 7th - MarketBeat
HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR - MarketBeat
Analyst Downgrade: How interest rate cuts could boost Capricor Therapeutics Inc stockWeekly Stock Analysis & Daily Profit Focused Stock Screening - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Trend Review: Why Capricor Therapeutics Inc. stock attracts high net worth investors2025 Buyback Activity & Safe Investment Capital Preservation Plans - moha.gov.vn
HBK Sorce Advisory LLC Raises Stake in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4% - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
Capricor Therapeutics prices $150M stock offering - MSN
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
With Capricor Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Top Medical Stocks To ResearchDecember 3rd - MarketBeat
Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal - Sahm
Capricor Therapeutics launches proposed public offering of common stock - MSN
Earnings Risk: Is ARK Autonomous Technology & Robotics stock cheap by valuation metricsMarket Trend Summary & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
How Capricor Therapeutics Inc. (4LN2) stock trades pre earningsQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.60%
자본화:
|
볼륨(24시간):